Idronoxil has been the subject of more than 50 peer-reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies. Whilst clinically tested in the past, idronoxil's journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored. Here, we summarize the current literature regarding the key cellular targets of idronoxil and the mechanisms by which idronoxil exerts its anticancer effects, laying a new foundation toward giving this unique molecule a second chance of contributing to the future of cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1568009620666200102122830 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-seq and Bulk RNA-seq Analysis in GC.
Recent Pat Anticancer Drug Discov
July 2024
School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian Province, China.
Article Synopsis
- Cellular senescence (CS) is linked to cancer progression, and this study explored its impact on gastric cancer (GC) by analyzing CS-related genes using the CellAge and TCGA databases.
- Researchers used a clustering method to categorize GC patients into two distinct subtypes (C1 and C2) based on these genes, revealing significant differences in gene expression, survival rates, and immune environments between the subtypes.
- A risk model was created identifying eight key genes, allowing for the classification of patients into high-risk (poor prognosis and greater drug resistance) and low-risk groups (better outcomes and potential benefits from immunotherapy).
ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma.
J Adv Res
February 2024
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. Electronic address:
Introduction: The immunosuppressive tumor microenvironment is a major barrier for chemotherapy. Different chemosensitization approaches to reinstate immunological surveillance for cancers that are immune quiescent at the outset, have thus been devised. Cancer-specific ENOX2 expression is correlated with abnormal cell growth and has been proposed as a cellular target for anti-cancer activity.
View Article and Find Full Text PDFThe role of isoflavones in augmenting the effects of radiotherapy.
Front Oncol
March 2023
Faculty of Engineering and Information Sciences, University of Wollongong, Wollongong, NSW, Australia.
Cancer is one of the major health problems and the second cause of death worldwide behind heart disease. The traditional soy diet containing isoflavones, consumed by the Asian population in China and Japan has been identified as a protective factor from hormone-related cancers. Over the years the research focus has shifted from emphasizing the preventive effect of isoflavones from cancer initiation and promotion to their efficacy against established tumors along with chemo- and radiopotentiating effects.
View Article and Find Full Text PDFIdronoxil as an Anticancer Agent: Activity and Mechanisms.
Curr Cancer Drug Targets
August 2021
Noxopharm Limited, Gordon, New South Wales, Australia.
Idronoxil has been the subject of more than 50 peer-reviewed publications over the last two decades. This isoflavone is an intriguing regulator of multiple signal transduction pathways, capable of causing a range of biological effects, including cell cycle arrest, apoptosis, an ability to stimulate the immune system, and inhibition of angiogenesis. These multifaceted actions suggest that idronoxil has the potential to synergize with, or complement, a wide range of cancer therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!